Telaah pustaka farmakogenetik Antiemetik Antagonis Reseptor 5-hidroksitriptamin 3 dalam onkologi Parmacogenetic of 5 Hydroxytriptamine 3B IN oncology- a review

Perwitasari, Dyah Aryani (2008) Telaah pustaka farmakogenetik Antiemetik Antagonis Reseptor 5-hidroksitriptamin 3 dalam onkologi Parmacogenetic of 5 Hydroxytriptamine 3B IN oncology- a review. Jurnal Sains dan Teknologi Farmasi, 13 (2). ISSN 1410 – 0177

	PDF (Telaah pustaka farmakogenetik Antiemetik Antagonis Reseptor 5-hidroksitriptamin 3 dalam onkologi Parmacogenetic of 5 Hydroxytriptamine 3B IN oncology- a review) - Published Version Available under License Creative Commons Public Domain Dedication. Download (540Kb)
	Postscript (Telaah pustaka farmakogenetik Antiemetik Antagonis Reseptor 5-hidroksitriptamin 3 dalam onkologi Parmacogenetic of 5 Hydroxytriptamine 3B IN oncology- a review) - Published Version Available under License Creative Commons Public Domain Dedication. Download (2110Kb)

Abstract

Nausea and vorniting are the most distressful side effects of cytotoxic drugs in cancer patiens. Anti emetics, such as 5 Hydroxytriptamine 3 reseptor antagonist (5 HT3), dopamine antagonist and neurokinin 1 antagonist are commonly used to reduce these side effect. However, the efficacy of current anticmetics about 70%-80% in cancer patiens treated with hight emetogenic cytotoxic drugs. One of the potential factors explaining this suboptimal response is variability in genes encoding enzymes anda proteins which play a role in metabolism, transport and receptors to anti-emetic drugs, beside other risk factors. This review presents the generic variation of the 5 HT3 reseptor, CYP2D6 anda ATP Binding Casette subfamily B member 1 (ABCB1). Moreover, pharmacogenetic studies exploring associations between genetic variation related to these anti-emetics and offycacy are reviewed. Keyword: anti-emetics, pharmaeogenetics, cancer

Actions (login required)

View Item